Literature DB >> 3119226

Identification and purification of a human lymphoid-specific octamer-binding protein (OTF-2) that activates transcription of an immunoglobulin promoter in vitro.

C Scheidereit1, A Heguy, R G Roeder.   

Abstract

The octamer sequence 5'-ATGCAAAT, in either orientation, serves as an upstream element in a variety of promoters and also occurs as a modular enhancer element. It is of particular interest in immunoglobulin genes since it is found in the upstream regions of all heavy and light chain promoters and in the heavy chain enhancer, both of which are known to be necessary for cell-specific expression. We report here the chromatographic separation of ubiquitous and B cell-specific octamer-binding proteins. The B cell factor was purified to homogeneity using affinity chromatography and consists of three peptides of 62, 61, and 58.5 +/- 1.5 kd. Each of the polypeptides was renatured after SDS-PAGE and shown to bind to the octamer sequence. The specific DNA binding activity of the pure B cell-specific factor was indistinguishable from that of the affinity-purified ubiquitous factor. This B cell-specific octamer-binding factor, in pure form, activated transcription from a kappa light chain promoter in vitro, thus demonstrating that it is indeed a B cell-specific transcription factor for this gene. In addition to the ubiquitous and B cell-specific octamer-binding factors, we identified several additional proteins, one of which is B cell-specific, that interact with the kappa promoter.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3119226     DOI: 10.1016/0092-8674(87)90101-2

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  131 in total

1.  Estrogen receptor level determines sex-specific in vitro transcription from the Xenopus vitellogenin promoter.

Authors:  B Corthésy; F X Claret; W Wahli
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  The Oct-1 POU domain mediates interactions between Oct-1 and other POU proteins.

Authors:  C P Verrijzer; J A van Oosterhout; P C van der Vliet
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

Review 3.  [Molecular-genetic mechanisms of developing the brain based on an embryonic Xenopus model].

Authors:  A G Zaraĭskiĭ
Journal:  Mol Biol (Mosk)       Date:  2004 Jan-Feb

4.  Activation of yeast polymerase II transcription by herpesvirus VP16 and GAL4 derivatives in vitro.

Authors:  D I Chasman; J Leatherwood; M Carey; M Ptashne; R D Kornberg
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

5.  Multiple hepatic trans-acting factors are required for in vitro transcription of the human alpha-1-antitrypsin gene.

Authors:  Y Li; R F Shen; S Y Tsai; S L Woo
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

6.  A distinct octamer-binding protein present in malignant melanoma cells.

Authors:  P M Cox; S M Temperley; H Kumar; C R Goding
Journal:  Nucleic Acids Res       Date:  1988-12-09       Impact factor: 16.971

7.  Distinguishable promoter elements are involved in transcriptional activation by E1a and cyclic AMP.

Authors:  K A Lee; J S Fink; R H Goodman; M R Green
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

8.  Interaction between a novel F9-specific factor and octamer-binding proteins is required for cell-type-restricted activity of the fibroblast growth factor 4 enhancer.

Authors:  L Dailey; H Yuan; C Basilico
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

9.  In silico analysis identifies CRISP3 as a potential peripheral blood biomarker for multiple myeloma: From data modeling to validation with RT-PCR.

Authors:  Dong Leng; Ran Miao; Xiaoxi Huang; Ying Wang
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

10.  Identification of a yeast protein with properties similar to those of the immunoglobulin heavy-chain enhancer-binding protein NF-muE3.

Authors:  H Beckmann; T Kadesch
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.